Alexis Desieno Sells 8,854 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 8,854 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total value of $32,494.18. Following the completion of the transaction, the chief financial officer now owns 121,976 shares of the company’s stock, valued at $447,651.92. This trade represents a 6.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Alexis Desieno also recently made the following trade(s):

• On Friday, November 15th, Alexis Desieno sold 25,118 shares of Cardlytics stock. The shares were sold at an average price of $3.43, for a total transaction of $86,154.74.

Cardlytics Trading Down 1.4 %

Shares of NASDAQ:CDLX opened at $3.44 on Wednesday. The firm has a fifty day moving average of $3.90 and a two-hundred day moving average of $4.78. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 12-month low of $2.89 and a 12-month high of $20.52. The firm has a market capitalization of $174.83 million, a P/E ratio of -0.56 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm had revenue of $67.06 million during the quarter, compared to analysts’ expectations of $57.77 million. During the same quarter last year, the firm earned ($0.26) earnings per share. The business’s revenue for the quarter was down 15.1% on a year-over-year basis. On average, equities analysts expect that Cardlytics, Inc. will post -1.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Cardlytics

A number of hedge funds have recently added to or reduced their stakes in CDLX. Geode Capital Management LLC lifted its stake in Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after acquiring an additional 73,484 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Cardlytics by 6.8% in the 2nd quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock valued at $6,685,000 after purchasing an additional 52,081 shares during the last quarter. RBF Capital LLC boosted its holdings in Cardlytics by 311.9% in the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock worth $1,562,000 after purchasing an additional 369,620 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Cardlytics by 3.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock worth $1,249,000 after buying an additional 11,388 shares during the last quarter. Finally, GSA Capital Partners LLP increased its position in Cardlytics by 1,273.2% during the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after buying an additional 354,474 shares during the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CDLX. Evercore ISI started coverage on shares of Cardlytics in a report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target on the stock. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research note on Thursday, November 7th. Finally, Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.